Citrate-capped gold nanoparticles for the label-free detection of ubiquitin C-terminal hydrolase-1 by Agarwal, S et al.
Analyst
PAPER
Cite this: Analyst, 2015, 140, 1166
Received 23rd October 2014,
Accepted 5th December 2014
DOI: 10.1039/c4an01935k
www.rsc.org/analyst
Citrate-capped gold nanoparticles for the
label-free detection of ubiquitin C-terminal
hydrolase-1†
Srishti Agarwal,‡a Priyanka Mishra,‡a Gururaj Shivange,a Naveena Kodipelli,a
María Moros,b Jesús M. de la Fuenteb and Roy Anindya*a
Ubiquitin C-terminal hydrolase-1 (UCH-L1) is a speciﬁc neuronal endoprotease that cleaves the speciﬁc
peptide bond between ubiquitin molecules. UCH-L1 is released in serum and cerebrospinal ﬂuid after
severe brain injury and is considered to be an important biomarker of brain injury. A common polymorph-
ism of UCH-L1 (S18Y) is also linked to a reduced risk of Parkinson’s disease. In addition to its function in
neuronal tissues, UCH-L1 may also play a part in the progression of certain non-neuronal cancers.
UCH-L1 is highly expressed in primary lung tumors and colo-rectal cancers, suggesting a role in tumori-
genesis. We report here the development of a sensitive and accurate UCH-L1 assay based on the surface
plasmon resonance (SPR) absorbance of gold nanoparticles. We created a unique UCH-L1 substrate con-
taining a ubiquitin molecule with two terminal thiol groups. This UCH-L1 substrate interacted with gold
nanoparticles via the terminal thiol groups and induced clustering of the nanoparticles, which was
detected by SPR absorbance at 650 nm. UCH-L1 proteolytically cleaved the substrate and the clustered
gold nanoparticles were dispersed and could be detected by a shift in the SPR absorbance to 530 nm.
This change in absorbance was proportional to the concentration of UCH-L1 and can be used for the
quantiﬁcation of functional UCH-L1. The currently available ﬂuorescence-based UCH-L1 assay is aﬀected
by a high background signal and a poor detection limit, especially in the presence of serum. The assay
reported here can detect concentrations of UCH-L1 as low as 20 ng ml−1 (0.8 nM) and the presence of
serum had no eﬀect on the detection limit. This assay could be adapted for the rapid determination
of the severity of brain injury and could also be applied to high-throughput screening of inhibitors of
UCH-L1 enzymatic activity in Parkinson’s disease and cancer.
1. Introduction
Ubiquitin is a polypeptide found in all eukaryotes and is made
up of 76 amino acids. The covalent attachment of ubiquitin to
cellular proteins targets them for proteasomal degradation. In
contrast, deubiquitination reverses the ubiquitination process
and is carried out by deubiquitinating enzymes. Based on
sequence similarity, deubiquitinating enzymes have been
classified into ubiquitin C-terminal hydrolases (UCHs) and
ubiquitin-specific proteases. Both classes are thiol proteases
that hydrolyze the isopeptide bond between the substrate and
the C-terminal glycine 76 of ubiquitin. Similar to the papain
family of cysteine proteases, the active site catalytic triad of the
UCH family of deubiquitinating enzymes consists of cysteine,
histidine and aspartate.
To date, four UCH enzymes have been identified in human
cells: UCH-L1, UCH-L3, UCH-L5 and BRCA1-associated protein
1. Of these enzymes, UCH-L1 is a highly specific neuronal
protein concentrated in the grey matter region of the brain.1
This 24 kDa enzyme constitutes 10% of neuronal proteins.2
The physiological role of UCH-L1 is to process a polyubiquitin
precursor that is important for the turnover of proteins in
neurons. Human studies have also linked UCH-L1 to degenera-
tive central nervous system diseases such as Parkinson’s
disease and Alzheimer’s disease.3 UCH-L1 has also been
shown to be a biomarker of neuronal loss during brain hemor-
rhage.4 Previous studies have established a few protein bio-
markers for brain injury.5,6 These include neuron-specific
enolase (NSE), glial protein S-100β, myelin basic protein and
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UCH-L1.7–10 Although NSE, S100β and myelin basic protein
have been shown to be released in the blood following brain
damage, conflicting results make their use as biomarkers
uncertain.11,12 In contrast, UCHL-1 protein is present exclu-
sively in neurons (unlike NSE and S100B, which are also
present in non-neural tissues).10 UCHL-1 (also known as PGP
9.5) was first detected as a brain-specific protein over 30 years
ago.2 It has been shown that UCHL-1 is released in cerebrosp-
inal fluid after ischemic and traumatic brain injury in rats.13
UCH-L1 has recently been discovered in cerebrospinal fluid
after serious brain injury and clinical studies have established
a strong correlation between the concentration of UCH-L1
and the outcome of treatment.14–16 As severe head injury that
damages internal brain tissues is a leading cause of death and
disability, a simple and inexpensive assay to determine
UCH-L1 in clinical samples would help doctors to quickly
determine the severity of brain damage in patients, monitor
the progress of treatment and ultimately predict the chance of
survival.
Although the expression of UCH-L1 is normally limited to
neuronal tissues,17 UCH-L1 levels have been found to be
increased in various malignancies, including acute lympho-
blastic leukemia, breast cancer, leukemia, medullary thyroid
carcinoma, non-small cell lung cancer, neuroblastoma, and in
prostate, esophageal, colo-rectal and pancreatic cancer, indi-
cating the involvement of UCHL-1 as an oncogene in the
pathogenesis of these tumors.18–27 This positive correlation
between UCH-L1 and tumor progression suggests that
UCH-L1 may play a part in cancer tumorigenesis. UCH-L1 has
also been shown to be induced as a response to tumor growth
and its expression has an antiproliferative eﬀect.28 As a result
of the up-regulation of UCH-L1 in many cancer tissues, high
levels of UCH-L1, particularly in non-neuronal tissues, may
serve as an early detection biomarker for tumors. Interestingly,
UCH-L1 itself could be a potential therapeutic target for
the treatment of cancer.28 A functional UCH-L1 assay that can
be adapted to a high-throughput setting would therefore
be useful in screening inhibitors. Moreover, a simple assay to
quantify UCHL-1 directly from clinical samples would help in
cancer staging and treatment at the time of diagnosis and
could ultimately improve patient care.
Our decision to develop an assay based on gold nanoparti-
cles was inspired by the study of Guarise et al.,29 who showed
that citrate-stabilized gold nanoparticles interact strongly with
head and tail thiol groups containing peptides, causing the
gold nanoparticles to form clusters. Gold nanoparticles about
30 nm in diameter absorb at 530 nm as a result of the exci-
tation of surface plasmons, which shift to longer wavelengths
(650 nm) when aggregates form. The progress of aggregate for-
mation can be followed with the naked eye as the color of the
solution changes from red to blue. Such a clear color change
during the aggregation or dispersion of gold nanoparticles
provides an elegant platform on which to develop an absorp-
tion-based colorimetric detection system without the require-
ment of sophisticated instrumentation. The possibility of
controlling nanoparticle aggregation has been exploited in
many areas of chemical sensing and enzyme bioassays.
Studies using gold nanoparticles have been based on superox-
ide dismutase, phosphatase, acetylcholine esterase, lactamase,
protease, lysozyme, nuclease, thrombin and glucose
oxidase.30–40 Several reports have also described protease
assays based on gold nanoparticles.34,41,42 However, gold nano-
particles have not been used for the detection of ubiquitinat-
ing or deubiquitinating enzymes.
We report here a novel method to detect UCH-L1. An artifi-
cial UCH-L1 substrate peptide with a ubiqiuitin moiety was
designed with two cysteine amino acids at the two termini.
The addition of this peptide caused rapid clustering of the
gold nanoparticles, followed by dispersion as a result of the
specific cleavage of the substrate peptide by UCH-L1 in a con-
centration-dependent manner. Under the test conditions, this
method can detect clinically reported levels of UCH-L1.
2. Experimental
Purification of recombinant human UCHL-1 and catalytic
mutant
Sequences encoding UCH-L1 were amplified from pGEFPC3-
hUCH-L1 (a generous gift from Dr Kerstin Brinkmann, Univer-
sity Hospital Cologne, Germany) by PCR and cloned into
pRSETA (Invitrogen) for expression in Esherichia coli and
protein purification. To study the enzymatic role of UCH-L1,
the key catalytic residue Cys at position 90 was mutated to Ala
by PCR-mediated site-directed mutagenesis. Wild type and
mutant UCH-L1 were overexpressed in E. coli and purified
using Ni-NTA agarose (Qiagen) following the manufacturer’s
protocol and were further purified by gel filtration using a
Superose-12 column (GE Healthcare).
UCHL-1 substrate design
UCHL-1 cleaves the peptide bond present between the C-term-
inal glycine of ubiquitin and a short peptide, preferably start-
ing with lysine.43 We therefore modified the ubiquitin
molecule with a lysine residue followed by six histidine amino
acids and, finally, a cysteine after the C-terminal glycine of
ubiquitin (ubiquitin-Lys-6xHis-Cys). Sequence coding of these
residues was introduced by an oligonucleotide primer during
PCR amplification of the ubiquitin gene. Ubiquitin with a
carboxy-terminal extension was cloned into pRSETA (Invitro-
gen) for expression in E. coli and protein purification. After
generating a UCHL-1 substrate with a single-terminal Cys
residue, we introduced the second Cys residue at the opposite
end of the molecule. The structure of ubiquitin clearly reveals
that Lys at position 63 is located exactly opposite to the
carboxy-terminus of ubiquitin (Fig. 1A). We mutated this Lys
residue to Cys by site-directed mutagenesis and generated a
UCH-L1 substrate with two terminal thiol groups. The UCH-L1
substrate was purified by single-step aﬃnity purification using
Ni-NTA chromatography as reported previously.44
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Purification of UCHL-1 substrate
The UCHL-1 substrate was overexpressed in E. coli and purified
by single-step aﬃnity purification using Ni-NTA chromato-
graphy.44 Bacterial cells expressing the UCHL-1 substrate were
lysed in extraction buﬀer (50 mM Tris-HCl, pH 8.0, 300 mM
sodium chloride, 0.1% Triton-X, 1 mM imidazole). The soluble
fraction was then heated for 10 min at 70 °C and the
denatured proteins were removed by centrifugation. The
recombinant protein was purified using Ni-NTA resin following
the manufacturer’s protocol.
Enzymatic hydrolysis of C-terminal extension of ubiquitin
The in vitro assay of UCH-L1 activity on the ubiquitin substrate
was performed by incubating 10 μg (6.7 μM) of UCHL-1 and
25 μg (50 μM) of ubiquitin in 50 μl of reaction buﬀer contain-
ing 20 mM Tris-HCl (pH 8.0), 0.5 mM EDTA, 5 mM DTT and
5% glycerol for 2 h at 30 °C. The cleavage of the ubiquitin
C-terminal extension peptide by UCH-L1 was analyzed by
gradient (4–15%) SDS-PAGE with Criterion gel (BioRad) using
10 μl of the reaction mix, followed by Coomassie Blue staining.
Synthesis of citrate-capped gold nanoparticles of 30 nm mean
diameter
To prepare gold nanoparticles of 30 nm diameter, 0.625 ml of
1% aqueous trisodium citrate and 50 ml of 0.25 mM chloro-
auric acid (HAuCl4) were refluxed together until the color
changed to wine red. The trisodium citrate acted as the redu-
cing agent as well as the stabilizing agent. To confirm the size
of the gold nanoparticles, 2.0 μl of a gold nanoparticle solution
at a concentration of 0.1 mg ml−1 in MilliQ H2O was dried on
a carbon-coated grid and viewed under a Leo 912 AB trans-
mission electron microscope at 120 kV (40 000× magnifi-
cation). The TEM measurements showed that the size of the
nanoparticles was 30 nm. The nanoparticles had a character-
Fig. 1 (A) Design of the UCH-L1 substrate containing two Cys at the two ends. The scissile peptide bond between Gly76 and Lys77 is marked with a
dotted line. (B) Sequence analysis of UCH-L1 substrate. Two terminal Cys residues are generated by site-directed mutagenesis. (C) SDS-PAGE analy-
sis of recombinant proteins. His-tag proteins were expressed in E.coli cells and puriﬁed using Ni-NTA agarose. Proteins were visualized by staining
with Coomassie Blue. (D) Outline of cleavage of substrate mediated by UCH-L1. UCH-L1 hydrolyzes the peptide bond between the Gly76 and Lys77
of the substrate peptide and results in a truncated UCH-L1 substrate. (E) SDS-PAGE analysis of proteolytic cleavage by UCH-L1. The puriﬁed 9 kDa
UCH-L1 substrate (50 μM) was incubated with puriﬁed UCH-L1 and C90A mutant UCH-L1 (6.7 μM). Cleavage mediated by UCH-L1was analyzed after
2 h by 4–15% gradient SDS-PAGE followed by Coomassie Blue staining. As a result of partial proteolytic cleavage, both the full-length and the trun-
cated UCH-L1 substrate (8 kDa) were formed. The arrow indicates the position of the truncated substrate.
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istic absorption peak at 530 nm in the UV–visible spectrum
and the concentration was calculated as 0.5 × 10−9 mol L−1.45
Aggregation of gold nanoparticles by UCHL-1 substrate
To induce the aggregation of the gold nanoparticles, a
1 : 2000 molar ratio of gold nanoparticles to UCHL-1 substrate
(1 μM) was incubated at 37 °C for 30 min in 1 ml of 10 mM
citrate buﬀer at pH 6. The aggregation of the gold nanoparti-
cles was then monitored by UV–visible absorption spectro-
metry using a U-3900 spectrophotometer (Hitachi). Similar
experiments were carried out with ubiquitin containing single-
terminal Cys as a negative control.
Dispersion of gold nanoparticles by UCHL-1
To induce the dispersion of the clustered gold nanoparticles,
recombinant UCH-L1 was added to the 30 nm gold nanoparti-
cles in the presence of serum in a reaction buﬀer containing
1 μM UCH-L1 substrate. The UCHL-1 concentration was
adjusted to close to the clinically relevant concentration
3.3 nM (100 ng ml−1) and then diluted further to 0.2 ng ml−1.
The reaction was then incubated for 2 h at 37 °C for
UCH-L1 mediated cleavage to take place. The dispersion of the
gold nanoparticles was then monitored by UV–visible absorp-
tion spectrophotometry to detect surface plasmon peaks.
Fluorescence-based UCHL-1 assay using Ubiquitin-AMC
Ub-AMC (Sigma) was dissolved in water to make a stock solu-
tion with a final concentration of 100 μM. Ub-AMC (5 μM) was
mixed with diﬀerent concentrations of UCH-L1 (0.2–100 ng
ml−1) in the presence of serum in a reaction buﬀer containing
10 mM Tris-HCl (pH 8.0) at 30 °C in a total volume of 300 μl.
AMC release was monitored with a Molecular Devices spectro-
fluorimeter with excitation at 340 nm and emission at 440 nm.
3. Results and discussion
Optimization of UCH-L1 assay
The UCH-L1 substrate was designed with two salient features.
The first was a short peptide extension C-terminal to the 76
amino acid ubiquitin protein. To make the substrate specific
to UCH-L1, the peptide extension starts with Lys as UCHL-1
preferentially cleaves the peptide bond between the C-terminal
Gly residue at position 76 of ubiquitin and the subsequent Lys
residue43 (Fig. 1A). After cleavage with UCH-L1, eight C-term-
inal amino acid residues are lost and the truncated substrate
is about 1 kDa shorter. The peptide extension contains six His
residues and a Cys residue at the C-terminus. We designed two
Cys residues at the two opposite ends of the molecule to facili-
tate the aggregation of the gold nanoparticles. The structure of
ubiquitin shows that the Lys at position 63 is located opposite
to the carboxy-terminus of ubiquitin (PDB entry 1ubq).46
Therefore, to generate two Cys residues at the head and tail
position of the molecule, a Cys residue was added to the
C-terminal end and the Lys residue at position 63 was mutated
to Cys by site-directed mutagenesis and confirmed by DNA
sequencing (Fig. 1B). The recombinant UCH-L1 substrate was
overexpressed in E. coli cells and purified by Ni-NTA aﬃnity
chromatography using the six His residues present in the
C-terminal peptide extension (Fig. 1C, lane 5). Recombinant
UCH-L1 and UCH-L1 catalytic site mutant (C90A) were also
overexpressed and purified from E. coli using Ni-NTA aﬃnity
chromatography with an N-terminal His-Tag (Fig. 1C, lanes
2 and 3, respectively).
In an eﬀort to demonstrate the deubiquitinase activity of
recombinant UCH-L1 using the artificial UCH-L1 substrate
in vitro, recombinant UCH-L1 was incubated with the UCH-L1
substrate for 2 h. An identical reaction was also carried out
with the C90A catalytic mutant of UCH-L1 as a control. The
proteolytic cleavage of the ubiquitin C-terminal extension
peptide was analyzed by 4–15% SDS-PAGE (Fig. 1D). Wild type
UCH-L1 cleaved the eight amino acids extension C-terminal
to the ubiquitin moiety, resulting in a truncated UCH-L1 sub-
strate with about a 1 kDa diﬀerence in molecular weight
(Fig. 1C, lane 2). SDS-PAGE analysis showed that the enzymatic
reaction was partially complete as both the full-length and the
truncated UCH-L1 substrate were present. Quantitation by
image analysis revealed that approximately 40% of the sub-
strate was hydrolyzed. We repeatedly observed such partial pro-
teolysis, even with prolonged incubation, and at present are
unable to provide any explanation for this observation. To
confirm that the peptide cleavage reaction was specifically due
to the enzymatic activity of UCH-L1, we incubated the UCH-L1
substrate with the C90A catalytic mutant of UCH-L1. As
expected, C90A UCH-L1 was not able to cleave the substrate
peptide and no truncated substrate was detected as a single
band on SDS-PAGE (Fig. 1C, lane 4). Together these results
suggest that the UCH-L1 substrate could be cleaved by recom-
binant UCH-L1 in vitro.
Aggregation and dispersion of gold nanoparticles
We hypothesized that the UCH-L1 substrate with head and tail
Cys thiol groups would trigger the clustering of gold nanoparti-
cles. If active UCH-L1 is then added to these clustered gold
nanoparticles, it would cleave the substrate and the gold nano-
particles would disperse again (Fig. 2A). To test this, we syn-
thesized 30 nm citrate-capped gold nanoparticles without any
surface modification and confirmed their size by TEM
(Fig. 2B). UV–visible absorption spectroscopic analysis revealed
a characteristic surface plasmon peak at 530 nm (Fig. 2C,
graph a). When the UCH-L1 substrate was added to the gold
nanoparticles, complete aggregation was observed in 30 min
and a color change from red to purple was seen (Fig. 2C, graph b).
We also determined that the minimum concentration of
UCH-L1 substrate required to induce the clustering of nano-
particles was 0.25 × 10−6 mol L−1 when the gold nanoparticles
and UCH-L1 substrate were added in a 1 : 2000 molar ratio. To
rule out the possibility of the non-specific aggregation of gold
nanoparticles, we mixed UCH-L1 substrate containing a single
Cys residue with gold nanoparticles. The UV–visible absorp-
tion spectra showed that the peptide containing a single Cys
thiol group was unable to induce clustering of the gold nano-
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particles (Fig. 2C, graph c). These results suggested that the
aggregation of nanoparticles was specifically due to the two
terminal Cys thiols present in the UCH-L1 substrate.
We then analyzed the time course of UCH-L1 substrate-
induced aggregation by monitoring the change in absorption.
As shown in Fig. 3A, the absorption at 650 nm (A650) gradually
increased and the absorption at 530 nm (A530) decreased in the
presence of the UCH-L1 substrate, suggesting a shift in plas-
monic resonance as a result of the formation of aggregates. To
demonstrate this more clearly, the A650/A530 ratio was plotted
against time (Fig. 3B). An increase in the fraction of aggregated
gold nanoparticles caused a gradual increase in the A650/A530
ratio. To test whether UCH-L1 mediated cleavage of its sub-
strate would inhibit the aggregation of gold nanoparticles, the
UCH-L1 substrate was added to the gold nanoparticles in
the presence of recombinant UCH-L1 and the spectral changes
were recorded. The addition of UCH-L1 prevented aggregate
formation and no increase in absorption was observed at
650 nm (Fig. 3C). This was probably a result of the lack of
availability of the substrate peptide due to proteolytic cleavage
by UCH-L1. As expected, we observed that the ratio of A650/A530
versus time remained almost unchanged (Fig. 3D). The small
increase in A650/A530 may be due to partial cleavage of the
UCH-L1 substrate. We also aggregated the gold nanoparticles
and carried out UCH-L1 mediated dispersion of the aggregated
nanoparticles in the presence of serum to mimic clinical
samples or bacterial or HeLa cell extracts that do not express
endogenous UCH-L1. We observed that the aggregation or dis-
persion of gold nanoparticles was not aﬀected as a result of
the presence of serum or cellular proteins and the results were
identical to Fig. 3A and B.
We then studied the time course of UCH-L1-induced dis-
persion of the aggregated gold nanoparticles in the presence
of serum, bacterial cell extracts or HeLa cell extracts. We
observed that the A650/A530 ratio also remained unchanged
(as in Fig. 3C and D), suggesting that the presence of serum or
cellular proteins had no eﬀect on the UCH-L1 induced dis-
persion of nanoparticle aggregates. To rule out cleavage of the
substrate by any non-specific proteases, we performed the gold
nanoparticle dispersion assay using mutant C90A UCH-L1. As
expected, the A650/A530 ratio also remained unchanged in the
presence of mutant C90A UCH-L1 (ESI, Fig. S2A†). We also
tested the substrate cleavage by adding the non-specific pro-
tease trypsin. Trypsin cleaves peptide bond carboxyl termini to
lysine and arginine. The UCH-L1 peptide substrate contains
ubiquitin followed by an eight amino acid extension starting
with lysine. As ubiquitin itself has seven lysine and nine argi-
nine residues, adding trypsin would cleave ubiquitin itself at
Fig. 2 (A) Outline of gold nanoparticle-based UCH-L1 assay. The
addition of the UCH-L1 substrate with two Cys thiol groups triggers the
aggregation processes, which can be detected by SPR absorbance at
650 nm. The addition of UCH-L1 cleaves the substrate peptide and dis-
perses the gold nanoparticles, which display SPR absorbance at 530 nm.
(B) TEM image of monodispersed citrate-capped gold nanoparticles
before aggregation. (C) Absorption spectra of gold nanoparticle solution
(0.5 nM in citrate buﬀer, pH 6.0) in the presence of (a) serum, (b)
UCH-L1 substrate (1 μM) with two terminal thiol groups and (c) UCH-L1
substrate with a single thiol group (1 μM).
Fig. 3 (A) Change of absorbance in the region 400–800 nm for gold
colloids (0.5 nM) on the addition of the UCH-L1 substrate (1 μM) with
two Cys thiols (curves taken at 5 min intervals). The dotted line rep-
resents the ﬁnal absorbance proﬁle reached after 30 min. (B) Variation in
A650 nm/A520 nm versus reaction time for the gold nanoparticle solutions
containing UCH-L1 substrate peptide (1 μM). (C) Change in the absor-
bance in the region 400–800 nm for aggregated gold colloids on the
addition of UCH-L1 substrate (1 μM) together with UCH-L1 (3.3 nM)
(values were recorded at 5 min intervals). The dotted line represents the
ﬁnal absorbance proﬁle reached after 30 min. (D) Variation of A650 nm/
A520 nm versus reaction time for the gold nanoparticle solutions contain-
ing UCH-L1 substrate peptide (1 μM) in the presence of 100 ng ml−1 (3.3
nM) UCH-L1.
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multiple positions, in addition to the lysine present at the
C-terminus to Gly 76 of ubiquitin (Fig. S2B†).
Fluorescence-based detection of UCHL-1 activity
The only available functional assay reported for UCH-L1 is
based on the hydrolysis of the artificial UCH-L1 substrate Ub-
AMC (Fig. 4A).47 We first wanted to determine the eﬃciency of
the Ub-AMC hydrolysis assay for the detection of the presence
of UCH-L1 using recombinant protein. Purified
UCH-L1 mediated hydrolysis of Ub-AMC resulted in the release
of AMC, which showed a peak absorption at 340 nm and emis-
sion at 440 nm (Fig. 4B, graph b). No background fluorescence
was detected in the absence of UCH-L1 (Fig. 4B, graph a). We
wanted to test the eﬃciency of UCH-L1 detection based on Ub-
AMC in clinical samples. We hydrolyzed Ub-AMC with UCH-L1
in the presence of serum to mimic clinical samples. When Ub-
AMC was incubated with UCH-L1 in the presence of serum,
AMC hydrolysis resulted in a distinct fluorescence emission
peak 440 nm (Fig. 4C, graph b). When UCH-L1 was omitted in
the reaction mixture, the fluorescence emission peak at
440 nm was still observed (Fig. 4C, graph a). This fluorescence
emission at 440 nm (Fig. 4C, graph a) was completely absent
in the serum-free samples (Fig. 4B, graph a). This suggested
that the presence of serum contributed a high background
fluorescence.
Comparison of sensitivity of the nanoparticle-based and the
fluorescence-based methods
To compare the sensitivity of the nanoparticle-based and fluo-
rescence-based methods for detecting functional UCH-L1, we
performed the UCH-L1 assay using a range of UCH-L1 concen-
trations in the absence and presence of serum. The concen-
tration range of UCH-L1 used in these reactions (1.8–100 ng
ml−1 UCH-L1) was decided by the amount of UCH-L1 released
into blood serum after brain injury (2–50 ng ml−1).15 We first
tested whether diluted UCH-L1 in the samples causes the dis-
persion of gold nanoparticles. We observed that concen-
trations of UCH-L1 as low as 20 ng ml−1 resulted a significant
change in the A650/A530 ratio (Fig. 5A). The presence of serum
did not influence the detection limit (Fig. 5A and S1†). We
also performed UCHL-1 catalyzed hydrolysis of Ub-AMC with a
similar range of concentrations of UCHL-1 in the absence of
serum. As shown in Fig. 5B, the presence of serum resulted in
high background fluorescence and a poor detection limit,
especially when UCH-L1 was present at lower concentrations.
A high background fluorescence as a result of the presence of
plasma proteins impeded the accurate detection of UCH-L1 in
the range 25–100 ng ml−1 (Fig. 5B). In contrast, the UCH-L1
detection assay based on gold nanoparticles was sensitive to
10–100 ng ml−1 of UCH-L1, even in the presence of serum or
cell extracts in the assay mixture (Fig. 5A and S1†). Further-
more, the assay based on SPR absorbance was superior with
respect to a lower limit of detection and the upper limit of
quantification. The slope of a linear regression analysis graph
was large enough to diﬀerentiate between small changes in
UCH-L1 concentration (Fig. 5A). In contrast, the calibration
graph derived from Ub-AMC hydrolysis did not show a linear
region in the presence of serum, whereas the fluorescence
varies linearly with UCH-L1 concentration (Fig. 5B). The cali-
bration graph obtained using the assay based on gold nano-
Fig. 4 (A) Schematic representation of the method for assaying UCH-L1
using Ubiquitin-AMC. Ub-AMC (5 μM) was mixed with UCH-L1 (100 ng
ml−1 or 3.3 nM) in the presence and absence of serum and the release of
AMC was monitored with excitation at 340 nm and emission at 440 nm.
(B) Emission spectra showing the increase in ﬂuorescence with cleavage
of the peptide bond by UCH-L1. Graph (a) represents the background
ﬂuorescence in the absence of UCH-L1. (C) Emission spectra showing
the increase in ﬂuorescence on cleavage of the peptide bond by
UCH-L1 in the presence of serum (b). Graph (a) shows the background
ﬂuorescence in the absence of UCH-L1 in the presence of serum.
Fig. 5 Calibration graph for the determination of UCH-L1 concen-
tration. (A) 30 nm gold nanoparticles (0.5 nM) and UCH-L1 substrate
with two terminal thiol groups (1 μM) were mixed with various concen-
trations of UCH-L1 in the absence or presence of serum for 2 h. The
calibration graph was obtained by plotting the variation of A650 nm/
A530 nm versus UCH-L1 concentration. (B) Ub-AMC (5 μM) was mixed
with diﬀerent concentrations of UCH-L1 in the absence or presence of
serum and the calibration graph was obtained by plotting the ﬂuore-
scence emission (440 nm) against UCH-L1 concentration.
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particles could be used to detect UCH-L1 at least two orders of
magnitude lower than calibration graph obtained using the
fluorescence-based assay. Together these results suggest that
the assay described here is better in terms of detection limit,
sensitivity, simplicity and lack of interference from cellular or
plasma proteins. Given the growing role of UCH-L1 in neuro-
degenerative disorders and cancer, we anticipate that this
simple assay will be useful in the high-throughput screening
of inhibitors. Moreover, the design of the ubiquitin-peptide
substrate described here could be tailored to assay other
UCHs.
4. Conclusion
This UCH-L1 assay based on gold nanoparticles can be used to
detect functional UCH-L1 in vitro via the hydrolysis of a short
peptide containing ubiquitin. The sensitivity is enhanced com-
pared with the presently available fluorescence-based assay.
The fluorescence-based assay using the hydrolysis of Ub-AMC
for the detection of UCH-L1 is aﬀected by high background
fluorescence and therefore is not sensitive. Our nanoparticle-
based assay does not require nanoparticle functionalization
and UCHL-1 can be detected by a simple analysis of SPR absor-
bance, even in the presence of plasma proteins or cell extracts.
The assay may be useful for detecting UCH-L1 in clinical
samples to determine the severity of brain injury. The assay is
also suitable for the high-throughput screening of UCH-L1
inhibitors to elucidate the etiological role of UCH-L1 in Parkin-
son’s disease and some cancers.
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